Mobile

An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in adolescents...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012117-21

An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in adolescents 12-13 years of age who were vaccinated in infancy with GSK Biologicals’ HBV vaccine (Engerix™-B)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the anti-HBs antibody response to a challenge dose of HBV vaccine (Engerix-B Kinder) in subjects 12-13 years of age, vaccinated with three doses of Engerix-B in infancy.

Critère d'inclusion

  • Antibody persistence and hepatitis B vaccine challenge in adolescents aged 12-13 years, vaccinated in infancy with three doses of GSK Biologicals’ HBV vaccine in routine practice

Liens